GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.
We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Explore more on our global website below.
How we help people thrive
At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place where people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
Explore on our global website
Our therapeutic areas
Pioneering research methods to help protect people from infections
Committed to delivering medicines for the treatment of people living with HIV
Bringing groundbreaking cancer therapies to our patients
Unlocking the science of the immune system to understand how the body reacts
Therapies where science aligns with our strategic approach
Our US business areas
Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK is a company where outstanding people can thrive.
We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccine and medicines development.
Purpose-built with a focus on acute and pressing needs in rare and women’s cancers
Continuously redefining treatment for COPD and asthma
Prioritizing R&D and commercial investment to improve patient outcomes
Protecting people from serious disease for well over 100 years
Fully dedicated to leaving no person living with HIV behind